Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|July 23, 2019
Acute Myeloid Leukemia with Myelodysplastic-Related Cytogenetics
Acute Myeloid Leukemia with Myelodysplastic-Related Cytogenetics
Advertisement
Case: A 68-Year-Old Man Withde novoAML
History and Physical:
- A 68-year-old man presented with significant fatigue and shortness of breath on exertion; reports low-grade fever for the past few days.
- PMH: mild hypertension, hypercholesterolemia, both medically managed; no history of malignancy
Laboratory work-up:
- WBC, 2.6 X 109/L
- ANC, 1.2 X 109/L
- Hb, 9.4 X 109/L
- Hct, 32%
- RBC, 3.3 X 109/L
- MCV, 121 fL
- PLT, 95 X 109/L
Bone marrow biopsy:65% blasts
Peripheral blood smear;70% blasts
FISH;del(5q), del (20q)
Diagnosis;AML, myelodysplasia-related cytogenetic abnormalities
Advertisement
Related to this article
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5